23 results on '"Essler, M."'
Search Results
2. P337 - DEPROMP-Study: PSMA-PET/CT prior to prostate biopsy: Enhancing prostate cancer detection and personalized management.
- Author
-
Krausewitz, P., Gaertner, F.C., Essler, M., Attenberger, U., Luetkens, J., Kristiansen, G., Ohlmann, C.H., Hauser, S., Ellinger, J., and Ritter, M.
- Subjects
- *
PROSTATE biopsy , *EARLY detection of cancer , *PROSTATE cancer - Published
- 2024
- Full Text
- View/download PDF
3. 1629P Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra).
- Author
-
Rahbar, K., Sarfaty, M., Peer, A., Leibowitz, R., Eiber, M., la Fougère, C., Prasad, V., Fendler, W.P., Rassek, P., Hasa, E., Dittmann, H., Bundschuh, R.A., Pabst, K.M., Kurtinecz, M., Korn, M., Essler, M., and Sartor, O.
- Subjects
- *
ANTIGENS - Published
- 2024
- Full Text
- View/download PDF
4. A0056 - DEPROMP Trial: The additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men.
- Author
-
Krausewitz, P., Gärtner, F.C., Essler, M., Attenberger, U., Luetkens, J., Kristiansen, G., Ohlmann, C.H., Hauser, S., Ellinger, J., and Ritter, M.
- Subjects
- *
PROSTATE biopsy , *PROSTATE cancer , *BIOPSY , *ADDITIVES - Published
- 2023
- Full Text
- View/download PDF
5. DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men—study protocol for a randomized trial.
- Author
-
Krausewitz, P., Bundschuh, R. A., Gaertner, F. C., Essler, M., Attenberger, U., Luetkens, J., Kristiansen, G., Muders, M., Ohlmann, C-H., Hauser, S., Ellinger, J., and Ritter, M.
- Subjects
- *
ENDORECTAL ultrasonography , *PROSTATE biopsy , *POSITRON emission tomography , *PROSTATE cancer , *IMAGE recognition (Computer vision) , *PROSTATE cancer patients - Abstract
Background: The primary objective is to determine the proportion of men with suspected prostate cancer (PCA) in whom the management plans are changed by additive gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) guided prostate biopsy (PET-TB) in combination with standard of care (SOC) using systematic (SB) and multiparametric magnetic resonance imaging-guided biopsy (MR-TB) compared with SOC alone. The major secondary objectives are to determine the additive value of the combined approach of SB + MR-TB + PET-TB (PET/MR-TB) for detecting clinically significant PCA (csPCA) compared to SOC; to determine sensitivity, specificity, positive and negative predictive value and diagnostic accuracy of imaging techniques, respective imaging classification systems, and each biopsy method; and to compare preoperatively defined tumor burden and biomarker expression and pathological tumor extent in prostate specimens. Methods: The DEPROMP study is a prospective, open-label, interventional investigator-initiated trial. Risk stratification and management plans after PET/MR-TB are conducted randomized and blinded by different evaluation teams of experienced urologists based on histopathological analysis and imaging information: one including all results of the PET/MR-TB and one excluding the additional information gained by PSMA-PET/CT guided biopsy. The power calculation was centered on pilot data, and we will recruit up to 230 biopsy-naïve men who will undergo PET/MR-TB for suspected PCA. Conduct and reporting of MRI and PSMA-PET/CT will be performed in a blinded fashion. Discussion: The DEPROMP Trial will be the first to evaluate the clinically relevant effects of the use of PSMA-PET/CT in patients with suspected PCA compared to current SOC. The study will provide prospective data to determine the diagnostic yields of additional PET-TB in men with suspected PCA and the impact on treatment plans in terms of intra- and intermodal changes. The results will allow a comparative analysis of risk stratification by each biopsy method, including a performance analysis of the corresponding rating systems. This will reveal potential intermethod and pre- and postoperative discordances of tumor stage and grading, providing the opportunity to critically assess the need for multiple biopsies. Trial registration: German Clinical Study Register DRKS 00024134. Registered on 26 January 2021. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. 18F-Octreotate Positron Emission Tomography (PET) for Target Volume Delineation in Stereotactic Radiation Therapy Planning of Glomus Tumors
- Author
-
Astner, S.T., Essler, M., Bundschuh, R.A., Beer, A., and Grosu, A.
- Published
- 2007
- Full Text
- View/download PDF
7. Diagnosis of periprosthetic loosening of total hip and knee arthroplasty using 68Gallium-Zoledronate PET/CT.
- Author
-
Touet, A., Koob, S., Kürpig, S., Roos, J., Roesch, F., Wirtz, DC., Essler, M., and Gaertner, FC.
- Subjects
- *
TOTAL knee replacement , *TOTAL hip replacement , *CHOICE (Psychology) , *REOPERATION , *CLINICAL medicine - Abstract
Purpose: Periprosthetic loosening is a major complication after total hip and knee arthroplasty. Early and accurate diagnosis is essential to choose the right therapeutic path and to avoid further complications. The aim of the study was to evaluate the diagnostic performance of 68Gallium-Zoledronate ([68Ga]Ga-DOTAZol) PET/CT in detecting periprosthetic loosening in total hip (THA) and total knee arthroplasty (TKA).This retrospective study included 26 patients with painful prosthesis (THA n = 17; TKA n = 16) and clinical suspicion of periprosthetic loosening, but without a confirmed diagnosis. Patients underwent [68Ga]Ga-DOTAZol PET/CT at least one year post-implantation. Diagnosis was confirmed through revision surgery or long-term clinical follow-up, with an observation period of at least 6 months. The analysis included both an assessment of the prosthesis as a unit and a separate evaluation of the individual components. Statistical analysis involved calculating sensitivity, specificity and accuracy using SPSS.Overall, a sensitivity of 77.8%, a specificity of 95.8% and an accuracy of 90.9% were found for detecting periprosthetic loosening, when considering the prosthesis as a unit. Individual component analyses showed a sensitivity of 71.4% and specificity of 96.2%.The use of [68Ga]Ga-DOTAZol PET/CT in periprosthetic loosening is a remarkable diagnostic tool and a promising approach. In comparison to established radionuclide tracers, 68Gallium-Zoledronate offers notable advantages due to its availability via 68Ge/68Ga-generators, improving its potential for clinical application.Methods: Periprosthetic loosening is a major complication after total hip and knee arthroplasty. Early and accurate diagnosis is essential to choose the right therapeutic path and to avoid further complications. The aim of the study was to evaluate the diagnostic performance of 68Gallium-Zoledronate ([68Ga]Ga-DOTAZol) PET/CT in detecting periprosthetic loosening in total hip (THA) and total knee arthroplasty (TKA).This retrospective study included 26 patients with painful prosthesis (THA n = 17; TKA n = 16) and clinical suspicion of periprosthetic loosening, but without a confirmed diagnosis. Patients underwent [68Ga]Ga-DOTAZol PET/CT at least one year post-implantation. Diagnosis was confirmed through revision surgery or long-term clinical follow-up, with an observation period of at least 6 months. The analysis included both an assessment of the prosthesis as a unit and a separate evaluation of the individual components. Statistical analysis involved calculating sensitivity, specificity and accuracy using SPSS.Overall, a sensitivity of 77.8%, a specificity of 95.8% and an accuracy of 90.9% were found for detecting periprosthetic loosening, when considering the prosthesis as a unit. Individual component analyses showed a sensitivity of 71.4% and specificity of 96.2%.The use of [68Ga]Ga-DOTAZol PET/CT in periprosthetic loosening is a remarkable diagnostic tool and a promising approach. In comparison to established radionuclide tracers, 68Gallium-Zoledronate offers notable advantages due to its availability via 68Ge/68Ga-generators, improving its potential for clinical application.Results: Periprosthetic loosening is a major complication after total hip and knee arthroplasty. Early and accurate diagnosis is essential to choose the right therapeutic path and to avoid further complications. The aim of the study was to evaluate the diagnostic performance of 68Gallium-Zoledronate ([68Ga]Ga-DOTAZol) PET/CT in detecting periprosthetic loosening in total hip (THA) and total knee arthroplasty (TKA).This retrospective study included 26 patients with painful prosthesis (THA n = 17; TKA n = 16) and clinical suspicion of periprosthetic loosening, but without a confirmed diagnosis. Patients underwent [68Ga]Ga-DOTAZol PET/CT at least one year post-implantation. Diagnosis was confirmed through revision surgery or long-term clinical follow-up, with an observation period of at least 6 months. The analysis included both an assessment of the prosthesis as a unit and a separate evaluation of the individual components. Statistical analysis involved calculating sensitivity, specificity and accuracy using SPSS.Overall, a sensitivity of 77.8%, a specificity of 95.8% and an accuracy of 90.9% were found for detecting periprosthetic loosening, when considering the prosthesis as a unit. Individual component analyses showed a sensitivity of 71.4% and specificity of 96.2%.The use of [68Ga]Ga-DOTAZol PET/CT in periprosthetic loosening is a remarkable diagnostic tool and a promising approach. In comparison to established radionuclide tracers, 68Gallium-Zoledronate offers notable advantages due to its availability via 68Ge/68Ga-generators, improving its potential for clinical application.Conclusion: Periprosthetic loosening is a major complication after total hip and knee arthroplasty. Early and accurate diagnosis is essential to choose the right therapeutic path and to avoid further complications. The aim of the study was to evaluate the diagnostic performance of 68Gallium-Zoledronate ([68Ga]Ga-DOTAZol) PET/CT in detecting periprosthetic loosening in total hip (THA) and total knee arthroplasty (TKA).This retrospective study included 26 patients with painful prosthesis (THA n = 17; TKA n = 16) and clinical suspicion of periprosthetic loosening, but without a confirmed diagnosis. Patients underwent [68Ga]Ga-DOTAZol PET/CT at least one year post-implantation. Diagnosis was confirmed through revision surgery or long-term clinical follow-up, with an observation period of at least 6 months. The analysis included both an assessment of the prosthesis as a unit and a separate evaluation of the individual components. Statistical analysis involved calculating sensitivity, specificity and accuracy using SPSS.Overall, a sensitivity of 77.8%, a specificity of 95.8% and an accuracy of 90.9% were found for detecting periprosthetic loosening, when considering the prosthesis as a unit. Individual component analyses showed a sensitivity of 71.4% and specificity of 96.2%.The use of [68Ga]Ga-DOTAZol PET/CT in periprosthetic loosening is a remarkable diagnostic tool and a promising approach. In comparison to established radionuclide tracers, 68Gallium-Zoledronate offers notable advantages due to its availability via 68Ge/68Ga-generators, improving its potential for clinical application. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas.
- Author
-
Astner ST, Dobrei-Ciuchendea M, Essler M, Bundschuh RA, Sai H, Schwaiger M, Molls M, Weber WA, Grosu AL, Astner, Sabrina T, Dobrei-Ciuchendea, Mihaela, Essler, Markus, Bundschuh, Ralf A, Sai, Heitetsu, Schwaiger, Markus, Molls, Michael, Weber, Wolfgang A, and Grosu, Anca-Ligia
- Abstract
Purpose: To evaluate the effect of trimodal image fusion using computed tomography (CT), magnetic resonance imaging (MRI) and (11)C-methionine positron emission tomography (MET-PET) for gross tumor volume delineation in fractionated stereotactic radiotherapy of skull base meningiomas.Patients and Methods: In 32 patients with skull base meningiomas, the gross tumor volume (GTV) was outlined on CT scans fused to contrast-enhanced MRI (GTV-MRI/CT). A second GTV, encompassing the MET-PET positive region only (GTV-PET), was generated. The additional information obtained by MET-PET concerning the GTV delineation was evaluated using the PET/CT/MRI co-registered images. The sizes of the overlapping regions of GTV-MRI/CT and GTV-PET were calculated and the amounts of additional volumes added by the complementing modality determined.Results: The addition of MET-PET was beneficial for GTV delineation in all but 3 patients. MET-PET detected small tumor portions with a mean volume of 1.6 +/- 1.7 cm(3) that were not identified by CT or MRI. The mean percentage of enlargement of the GTV using MET-PET as an additional imaging method was 9.4% +/- 10.7%.Conclusions: Our data have demonstrated that integration of MET-PET in radiotherapy planning of skull base meningiomas can influence the GTV, possibly resulting in an increase, as well as in a decrease. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
9. Involvement of the GTPase Rho in the cellular uptake of low density lipoprotein by human skin fibroblasts
- Author
-
Hrboticky, N., Feldmeer, T., Essler, M., Wiedemann, A., and Aepfelbacher, M.
- Subjects
- *
GUANOSINE triphosphatase , *LOW density lipoproteins - Abstract
Members of the Rho subfamily of small GTPases have been implicated in the regulation of endocytosis of ligand/receptor complexes localised to clathrin-coated pits. In this paper, we investigated the role of Rho A in the post-receptor regulation of cellular uptake and metabolism of native low density lipoprotein (LDL) by primary human skin fibroblasts. Incubations of cells with the selective Rho GTPase inhibitor C3-transferase (C3T) upregulated the binding, lysosomal degradation and cell accumulation of labelled LDL. The rate of internalisation of surface-bound LDL was also higher in C3T-treated cells. Single cell injections with C3T and dominant active V14Rho confirmed the negative regulation of LDL uptake by Rho. While cells injected with C3T internalised more 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (diI)-labelled LDL, diI-LDL internalisation was dramatically suppressed in cells injected with the constitutively active V14Rho. The negative regulation of LDL uptake by Rho appeared to be independent of changes in the actin cytoskeleton. An increasing number of naturally occurring toxins and serum factors have been shown to influence Rho GTPase signalling cascades. The herein described post-translational regulation of LDL internalisation may modulate cell events occurring subsequent to cellular lipoprotein uptake. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
10. Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga–PSMA uptake in LNCaP cells.
- Author
-
Mathy, C. S., Mayr, T., Kürpig, S., Meisenheimer, M., Dolscheid-Pommerich, R. C., Stoffel-Wagner, B., Kristiansen, G., Essler, M., Muders, M. H., and Bundschuh, R. A.
- Subjects
- *
ABIRATERONE acetate , *CASTRATION-resistant prostate cancer , *PROSTATE cancer patients , *SECRETION , *POSITRON emission tomography , *PROTEIN expression - Abstract
Background: In recent years, a variety of innovative therapeutics for castration-resistant prostate cancer have been developed, including novel anti-androgenic drugs, such as abiraterone or VPC-13566. Therapeutic monitoring of these pharmaceuticals is performed either by measuring PSA levels in serum or by imaging. PET using PSMA ligands labeled with Fluor-18 or Gallium-68 is the most sensitive and specific imaging modality for detection of metastases in advanced prostate cancer. To date, it remains unclear how PSMA expression is modulated by anti-hormonal treatment and how it correlates with PSA secretion. Methods: We analyzed modulation of PSMA-mRNA and protein expression, 68Ga–PSMA uptake and regulation of PSA secretion by abiraterone or VPC-13566 in LNCaP cells in vitro. Results: We found that abiraterone and VPC-13566 upregulate PSMA protein and mRNA expression but block PSA secretion in LNCaP cells. Both anti-androgens also enhanced 68Ga–PSMA uptake normalized by the number of cells, whereas abiraterone and VPC-13566 reduced 68Ga–PSMA uptake in total LNCaP monolayers treated due to cell death. Conclusion: Our data indicate that PSA secretion and PSMA expression are differentially regulated upon anti-androgen treatment. This finding might be important for the interpretation of 68Ga–PSMA PET images in monitoring therapies with abiraterone and VPC-13566 in prostate cancer patients, but needs to be validated in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours.
- Author
-
Gaertner, F.C., Plum, T., Kreppel, B., Eppard, E., Meisenheimer, M., Strunk, H., Bundschuh, R.A., Sinnes, J.P., Rösch, F., and Essler, M.
- Subjects
- *
SOMATOSTATIN receptors , *POSITRON emission tomography , *TUMORS , *LIVER metastasis - Abstract
[68Ga]Ga-DATA-TOC is a new radiolabelled somatostatin-analogue for positron emission tomography (PET) imaging of neuroendocrine tumours. Its advantage over DOTA-conjugated compounds is the possibility for high-efficiency labelling with gallium-68 quickly at room temperature with high reliability and without the need for product purification, which enables the development of an instant kit-type labelling method. We evaluated its imaging characteristics in patients with neuroendocrine tumours in comparison to [68Ga]Ga-DOTA-TOC. 19 patients imaged with [68Ga]Ga-DATA-TOC were retrospectively analysed and uptake in normal tissues was compared with a group of 19 patients imaged with [68Ga]Ga-DOTA-TOC. 10 patients imaged with [68Ga]Ga-DATA-TOC had a history of [68Ga]Ga-DOTA-TOC imaging before and were additionally analysed to obtain biodistribution data of both tracers in the same patients. In 5 patients showing stable disease between both examinations, tumour uptake, lesion detectability and lesion conspicuity of both tracers were evaluated. Uptake of [68Ga]Ga-DATA-TOC in normal organs with expression of the somatostatin receptor was 25–47% lower compared to [68Ga]Ga-DOTA-TOC. Background of [68Ga]Ga-DATA-TOC was 40–41% lower in the liver. A higher retention of [68Ga]Ga-DATA-TOC was observed in the blood (up to 67%) and in the lungs (up to 44%). Tumour uptake (SUV) was 22–31% lower for [68Ga]Ga-DATA-TOC. However, no significant differences were observed for tumour-to-background ratios and lesion detectability. Regarding liver metastases, [68Ga]Ga-DATA-TOC uptake (SUV) reached 69–73% of [68Ga]Ga-DOTA-TOC uptake, but tumour-to-background ratios of [68Ga]Ga-DATA-TOC were 105–110% of [68Ga]Ga-DOTA-TOC ratios. We demonstrated the feasibility of the new PET tracer [68Ga]Ga-DATA-TOC for imaging of patients with neuroendocrine tumours, showing a comparable performance to [68Ga]Ga-DOTA-TOC. [68Ga]Ga-DATA-TOC has the potential for development of an instant kit-type labelling method at room temperature similar to 99mTc-labelled radiopharmaceuticals, which might help to increase the availability of 68Ga-labelled somatostatin analogues for clinical routine use. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
- Author
-
Rahbar, K., Boegemann, M., Yordanova, A., Eveslage, M., Schäfers, M., Essler, M., and Ahmadzadehfar, H.
- Subjects
- *
PROSTATE cancer treatment , *PROSTATE cancer prognosis , *METASTASIS , *CASTRATION-resistant prostate cancer , *PROSTATE-specific antigen - Abstract
Aim: Our aim was to evaluate overall survival and parameters prognosticating longer survival in a large and homogeneous group of patients treated with Lu-PSMA-617 radioligand therapy with heavily pretreated advanced metastatic castration resistant prostate cancer. Methods: A total of 104 patients were treated with 351 cycles of Lu-PSMA-617. Prostate specific antigen (PSA) changes after the first cycle of therapy were documented prior to a second cycle. Patients were followed-up for overall survival (OS). Any PSA decline, PSA decline ≥50%, initial PSA, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), visceral metastases and cumulative injected activity were analyzed and evaluated according to OS. Multivariable analysis with parameters with a p-value ≤0.05 in univariate analysis was performed, additionally adjusting for age and presence of visceral metastases. Results: A total of 51 patients (49%) died during the observation period. The majority of patients (97%) presented with bone metastases, 77% with lymph node metastases and 32% with visceral metastases. All patients were treated with at least one line of chemotherapy. Either abiraterone or enzalutamide had been given in 100% of the patients. Any PSA decline occurred in 70 (67%) and a PSA decline ≥50% in 34 (33%) of patients after the first cycle. The median OS was 56.0 weeks (95%CI: 50.5-61.5). Initial PSA decline ≥50%, initial LDH, visceral metastases, second line chemotherapy or prior radium-223 did not have an effect on survival, whereas any initial PSA decline, initial ALP <220 U/L and cumulative injected activity ≥18.8 GBq were associated with a longer survival. A step-by-step analysis revealed a PSA decline ≥20.87% as the most noticeable cut-off prognosticating longer survival, which remained an independent prognosticator of improved OS in the multivariate analysis. Conclusion: Lu-PSMA-617 RLT is a new effective therapeutic and seems to prolong survival in patients with advanced mCRPC pretreated with chemotherapy, abiraterone and/or enzalutamide. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours.
- Author
-
Yordanova, A., Ahmadzadehfar, H., Gonzalez-Carmona, M., Strassburg, C., Mayer, K., Feldmann, G., Schmidt-Wolf, I., Lingohr, P., Fischer, S., Kristiansen, G., and Essler, M.
- Subjects
- *
NEUROENDOCRINE tumors , *RADIOTHERAPY treatment planning , *ONCOLOGIC surgery , *NUCLEAR medicine , *DISEASE incidence , *TUMOR treatment - Abstract
Neuroendocrine tumours (NET) are rare neoplasms, but the incidence is permanently increasing. Most of the NETs are slow proliferating and clinically silent, and for that reason, they are often diagnosed at a stage with advanced disease. The complexity and diversity of the NET-biology require the treatment of patients in specialised centres to guarantee a qualified, multidisciplinary treatment planning. At our institution, we developed an interdisciplinary model for the assessment and treatment of NET. The aim was to adapt the guidelines to the clinical practice, exchange of current knowledge, and a tailored approach to the individual patient. In our team are included medical professionals from pathology, radiology, oncology, gastroenterology, oncological surgery, and nuclear medicine. In this paper, we describe step-by-step a procedural algorithm for the management of patients with neuroendocrine tumours, focusing on midgut-NETs in terms of therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Symmetric multifocal bone marrow involvement diagnosed by whole-body magnetic resonance imaging in a patient with B lymphoblastic lymphoma.
- Author
-
Eichner R, Wörtler K, Essler M, Rudelius M, Peschel C, Ringshausen I, Götze K, Eichner, Ruth, Wörtler, Klaus, Essler, Markus, Rudelius, Martina, Peschel, Christian, Ringshausen, Ingo, and Götze, Katharina
- Published
- 2013
- Full Text
- View/download PDF
15. 1394P Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study.
- Author
-
O'Sullivan, J., Heinrich, D., Castro Marcos, E., George, S., Song, D.Y., Dizdarevic, S., Baldari, S., Essler, M., de Jong, I.J., Lastoria, S., Hammerer, P.G., Tombal, B., James, N.D., Verholen, F., Meltzer, J., Sandström, P., and Sartor, O.
- Subjects
- *
CASTRATION-resistant prostate cancer , *ALKALINE phosphatase , *OVERALL survival - Published
- 2022
- Full Text
- View/download PDF
16. 593P Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC).
- Author
-
Higano, C.S., Dizdarevic, S., Sundar, S., Agarwal, N., Essler, M., Song, D., George, S., Shore, N.D., Kurtinecz, M., Verholen, F., Sandström, P., Sartor, O., and George, D.J.
- Subjects
- *
CASTRATION-resistant prostate cancer , *SCIENTIFIC observation - Published
- 2021
- Full Text
- View/download PDF
17. Safety And Clinical Outcomes Of Radium-223 With Concomitant Radiotherapy Or Subsequent Treatment With The Investigational Agent 177Lu-PSMA In Patients With Metastatic Castration-Resistant Prostate Cancer: An Interim Analysis Of The REASSURE Study.
- Author
-
Song, D., Zimberg, S.H., Conti, P., la Fougère, C., Essler, M., Kramer, G., Ellinger, J., Sylvester, J.E., Paganelli, G., Peer, A., Bögemann, M., George, S., Tomaszewski, J., Meltzer, J., Sandström, P., Babajanyan, S., Nordquist, L., and Sartor, O.
- Subjects
- *
INVESTIGATIONAL therapies , *CASTRATION-resistant prostate cancer , *PROSTATE cancer , *RADIOTHERAPY - Published
- 2020
- Full Text
- View/download PDF
18. Measuring and modeling patient-specific distributions of material properties in abdominal aortic aneurysm wall.
- Author
-
Reeps, C., Maier, A., Pelisek, J., Härtl, F., Grabher-Meier, V., Wall, W., Essler, M., Eckstein, H.-H., and Gee, M.
- Subjects
- *
ANEURYSMS , *VASCULAR diseases , *ABDOMINAL aorta , *FINITE element method , *NUMERICAL analysis - Abstract
Both the clinically established diameter criterion and novel approaches of computational finite element (FE) analyses for rupture risk stratification of abdominal aortic aneurysms (AAA) are based on assumptions of population-averaged, uniform material properties for the AAA wall. The presence of inter-patient and intra-patient variations in material properties is known, but has so far not been addressed sufficiently. In order to enable the preoperative estimation of patient-specific AAA wall properties in the future, we investigated the relationship between non-invasively assessable clinical parameters and experimentally measured AAA wall properties. We harvested n = 163 AAA wall specimens ( n = 50 patients) during open surgery and recorded the exact excision sites. Specimens were tested for their thickness, elastic properties, and failure loads using uniaxial tensile tests. In addition, 43 non-invasively assessable patient-specific or specimen-specific parameters were obtained from recordings made during surgery and patient charts. Experimental results were correlated with the non-invasively assessable parameters and simple regression models were created to mathematically describe the relationships. Wall thickness was most significantly correlated with the metabolic activity at the excision site assessed by PET/CT ( ρ = 0.499, P = 4 × 10) and to thrombocyte counts from laboratory blood analyses ( ρ = 0.445, P = 3 × 10). Wall thickness was increased in patients suffering from diabetes mellitus, while it was significantly thinner in patients suffering from chronic kidney disease (CKD). Elastic AAA wall properties had significant correlations with the metabolic activity at the excision site (PET/CT), with existent calcifications, and with the diameter of the non-dilated aorta proximal to the AAA. Failure properties (wall strength and failure tension) had correlations with the patient's medical history and with results from laboratory blood analyses. Interestingly, AAA wall failure tension was significantly reduced for patients with CKD and elevated blood levels of potassium and urea, respectively, both of which are associated with kidney disease. This study is a first step to a future preoperative estimation of AAA wall properties. Results can be conveyed to both the diameter criterion and FE analyses to refine rupture risk prediction. The fact that AAA wall from patients suffering from CKD featured reduced failure tension implies an increased AAA rupture risk for this patient group at comparably smaller AAA diameters. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
19. Assessment of tumor volumes in skull base glomus tumors using Gluc-Lys[(18)F]-TOCA positron emission tomography.
- Author
-
Astner ST, Bundschuh RA, Beer AJ, Ziegler SI, Krause BJ, Schwaiger M, Molls M, Grosu AL, Essler M, Astner, Sabrina T, Bundschuh, Ralph A, Beer, Ambros J, Ziegler, Sibylle I, Krause, Bernd J, Schwaiger, Markus, Molls, Michael, Grosu, Anca L, and Essler, Markus
- Abstract
Purpose: To assess a threshold for Gluc-Lys[(18)F]-TOCA positron emission tomography (PET) in target volume delineation of glomus tumors in the skull base and to compare with MRI-based target volume delineation.Methods and Materials: The threshold for volume segmentation in the PET images was determined by a phantom study. Nine patients with a total of 11 glomus tumors underwent PET either with Gluc-Lys[(18)F]-TOCA or with (68)Ga-DOTATOC (in 1 case). All patients were additionally scanned by MRI. Positron emission tomography and MR images were transferred to a treatment-planning system; MR images were analyzed for lesion volume by two observers, and PET images were analyzed by a semiautomated thresholding algorithm.Results: Our phantom study revealed that 32% of the maximum standardized uptake value is an appropriate threshold for tumor segmentation in PET-based target volume delineation of gross tumors. Target volume delineation by MRI was characterized by high interobserver variability. In contrast, interobserver variability was minimal if fused PET/MRI images were used. The gross tumor volumes (GTVs) determined by PET (GTV-PET) showed a statistically significant correlation with the GTVs determined by MRI (GTV-MRI) in primary tumors; in recurrent tumors higher differences were found. The mean GTV-MRI was significantly higher than mean GTV-PET. The increase added by MRI to the common volume was due to scar tissue with strong signal enhancement on MRI.Conclusions: In patients with glomus tumors, Gluc-Lys[(18)F]-TOCA PET helps to reduce interobserver variability if an appropriate threshold for tumor segmentation has been determined for institutional conditions. Especially in patients with recurrent tumors after surgery, Gluc-Lys[(18)F]-TOCA PET improves the accuracy of GTV delineation. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
20. Renal accumulation of [111In]DOTATOC in rats: influence of inhibitors of the organic ion transport and diuretics.
- Author
-
Stahl, A. R., Wagner, B., Poethko, T., Perutka, M., Wester, H. J., Essler, M., Heemann, U., Schwaiger, M., and Lutz, J.
- Subjects
- *
THERAPEUTICS , *DIURETICS , *LABORATORY rats , *ORGANS (Anatomy) , *CIMETIDINE - Abstract
Radiation exposure to the kidney limits therapy with radiometal labelled DOTATOC. This study evaluates the organic anion and cation transport (inhibitors: probenecid and cimetidine/dexamethason) as well as diuresis (furosemide and mannitol) regarding renal uptake of [111In]DOTATOC. One hundred eight male Fisher rats were injected with [111In]DOTATOC via the tail vein. Prior to activity injection a total of 84 rats underwent injection with probenecid vs. sodium chloride 0.9% (48 rats), cimetidine vs. dexamethasone vs. sodium chloride 0.9% (18 rats), and furosemide vs. mannitol vs. sodium chloride 0.9% (18 rats). Rats were sacrificed at predetermined time points up to 48 h after activity injection. Kidneys, adrenal glands, pancreas, spleen, blood, liver, and muscle were harvested and injected activity per gram tissue was determined. Autoradiographic images of the kidneys were acquired in a total of 24 rats. Probenecid led to a reduction in renal uptake by up to 30% while not significantly changing the activity accumulation in the other organs investigated. This reduction was attributable to the renal cortex (ratio cortex/medulla 1.72 vs. 1.99; p = 0.006). Cimetidine and dexamethasone had no effect in any of the organs. Furosemide led to a 44% increase in renal activity accumulation attributable to enhanced renal medullary uptake (ratio cortex/medulla 1.44 versus 1.69; p = 0.006). Mannitol had no effect on renal activity uptake. Inhibition of the organic anion transport by probenecid may help reduce renal uptake regarding therapy with radiometal labelled DOTATOC. The enhancing effect of furosemide may be unfavourable for therapy. The results must be confirmed by human studies. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
21. 306 - Vascular expression of prostate-specific membrane antigen in renal tumors: Diagnostic and prognostic role.
- Author
-
Tolkach, Y., Spatz, S., Jung, K., Stephan, C., Busch, J., Ralla, B., Rabien, A., Feldmann, G., Brossart, P., Bundschuh, R., Ahmadzadehfar, H., Essler, M., Toma, M., Müller, S., Ellinger, J., Hauser, S., and Kristiansen, G.
- Published
- 2018
- Full Text
- View/download PDF
22. EP-1310: 68Ga-PSMA-PET/CT imaging of localized prostate cancer patients for IMRT with integrated boost.
- Author
-
Thomas, L., Kantz, S., Hung, A., Monaco, D., Essler, M., Strunk, H., Thomas, C., Laub, W., and Bundschuh, R.
- Published
- 2017
- Full Text
- View/download PDF
23. PD-0279 VALUE OF 18F-FDG-PET/CT AFTER STEREOTACTIC BODY RADIATION THERAPY FOR STAGE I NON-SMALL CELL LUNG CANCER
- Author
-
Andratschke, N., Wantke, J., Mayer, B., Bundschuh, R.A., Haller, B., Astner, S.T., Molls, M., and Essler, M.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.